About
Contact & Profiles
A5058391336
Research Areas
- Prenatal Screening and Diagnostics
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
Voxelotor is a first-in-class sickle hemoglobin-polymerization inhibitor that was approved in 2019 by the US Food and Drug Administration for treatment of patients with cell disease (SCD) aged ≥12 years; 2021, approval extended to children SCD 4 11 years. Additionally, both Ministry Health Prevention United Arab Emirates European Commission granted marketing authorization voxelotor September 2021 February 2022, respectively, adults pediatric Thus, additional information on patient experience...
10.1155/2023/7533111
article
EN
cc-by
BioMed Research International
2023-01-01
Coming Soon ...